Market Newsdesk

HONG KONG, Jan. 12, 2021 /PRNewswire/ — Lion Group Holding Ltd. (“Lion” or “the Company”) (NASDAQ: LGHL), operator of an all-in-one trading platform that offers a wide spectrum of products and services with a focus on Chinese investors, today announced it will acquire 100% of Lion FinTech Group Limited for an amount to be agreed upon with a  definitive agreement expected to be signed by March 31, 2021. Through its subsidiary, Royal Lion Middle East DMCC, Lion FinTech holds a proprietary trading license for crypto assets in Dubai. The Company expects the acquisition to close in the first quarter of 2021. 

Royal Lion Middle East DMCC holds its proprietary trading license with the Dubai Multi Commodities Centre (“DMCC”), and functions as a central counterparty in the crypto asset market. Upon expected completion of the acquisition, Lion’s clients will have access to trade legal tender crypto currencies under regulated conditions, ensuring safe transactions. Royal Lion Middle East DMCC is the only license holder with DMCC that supports FIAT currency, which, following the acquisition, will provide Lion’s clients with an efficient and secure platform to exchange FIAT currencies with crypto currencies. With the license authorized for relevant financial activities and business resources, Lion plans to offer its clients crypto assets-backed trust funds as the best alternative avenue to invest in crypto assets.

Mr. Chunning (Wilson) Wang, Chief Executive Officer at Lion, commented, “This acquisition will bridge the gap between traditional financial markets and the crypto asset market, providing a simple and secure crypto trading platform for our clients. We believe the introduction of crypto trading will enable clients to implement more complex strategies with speed and efficiency, and unlock dynamic trading using smart contracts. Investors increasingly depend on speed and advanced capabilities to add incremental value to their portfolios, and we are excited to offer these tools to our clients following the expected acquisition of Lion FinTech.”

Mr. Wang Jian, Chairman of Lion, owns 100% of Lion FinTech Group Limited, the controlling company of Royal Lion Investment Limited (“RLIL”). An investment company owned by a member of the United Arab Emirates (UAE) royal family also holds equity interest in RLIL. RLIL wholly owns Royal Lion Middle East DMCC.

About Lion

Lion Group Holding Ltd. (NASDAQ: LGHL) operates an all-in-one trading platform that offers a wide spectrum of products and services with a focus on Chinese investors. Through its state-of-the-art technology, Lion offers contract-for-difference (CFD) trading, insurance brokerage, futures brokerage, and securities brokerage on its platform, which can be accessed through applications available on the iOS, Android, Windows, and macOS systems. Lion’s customers are well-educated and affluent Chinese individual investors residing both inside and outside the PRC as well as institutional clients in Hong Kong. Additional information may be found at http://ir.liongrouphl.com.

Forward-Looking Statements

This press release contains, “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Lion’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Lion’s expectations with respect to future performance and anticipated financial impacts of the Business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Lion and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the inability to maintain the listing of the post-acquisition company’s ADSs on NASDAQ following the business combination; (2) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the transactions described herein; (3) the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (4) costs related to the business combination; (5) changes in applicable laws or regulations; (6) the possibility that Lion may be adversely affected by other economic, business, and/or competitive factors; and (7) other risks and uncertainties to be identified in the proxy statement/prospectus relating to the business combination, including those under “Risk Factors” therein, and in other filings with the Securities and Exchange Commission (“SEC”) made by Lion. Lion cautions that the foregoing list of factors is not exhaustive. Lion cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Lion does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law.

Contacts

Lion Group Holding

Tel: +852 2820 9011
Email: [email protected]

ICR, LLC

William Zima

Tel: +1 203 682 8233
Email: [email protected]  

View original content:http://www.prnewswire.com/news-releases/lion-announces-acquisition-of-lion-fintech-group-301206128.html

SOURCE Lion Group Holding Ltd.

 

McCaffery brings 30 years of experience helping carriers and enterprises evolve their business communications 

WESTFORD, Mass., Jan. 12, 2021 /PRNewswire/ — Ribbon Communications Inc. (Nasdaq: RBBN), a global provider of real time communications software and network solutions to service providers, enterprises, and critical infrastructure sectors, today announced that Steve McCaffery has joined the company as Executive Vice President of Sales for the EMEA (Europe, Middle East and Africa) and APAC (Asia Pacific) regions. He reports directly to Ribbon’s Chief Executive Officer and President, Bruce McClelland.

“With his track record of growing revenues in EMEA and APAC, and significant experience as a trusted advisor to many of the world’s largest carriers and enterprises, Steve will play a pivotal role in helping us execute on our growth plans,” said Mr. McClelland. “I look forward to working together and having Steve join my leadership team.”

Mr. McCaffery has more than 30 years’ experience leading sales and marketing teams and working with global fixed and mobile operators. Before joining Ribbon, he was the CEO of consulting business GOT2, advising technology companies in the convergence, wireless, broadband and video spaces. Previously, McCaffery managed a $2.4B international business addressing both carrier and enterprise customers and was a member of the executive team at ARRIS following the acquisition of Motorola Home. Prior to his time at ARRIS, he built and developed Native Networks, a venture-backed company in the data space which was purchased by Alcatel-Lucent, where he helped manage the Optical Networks business in EMEA.

“I’m thrilled to be joining Ribbon at this critical juncture,” said Mr. McCaffery. “The company is positioned for success and I look forward to working with the leadership and sales teams to expand our footprint  in the EMEA and APAC markets.”

McCaffery succeeds Fernando Valdivielso, who is leaving the company to pursue other interests.  “I want to thank Fernando for his accomplishments since the Ribbon-ECI merger, including integrating the APAC and EMEA sales teams,” added Mr. McClelland. “We wish him the best in his future endeavors.”

About Ribbon
Ribbon Communications (Nasdaq: RBBN) delivers global communications software and packet and optical network solutions to service providers, enterprises and critical infrastructure sectors. We engage deeply with our customers, helping them modernize their networks for improved competitive positioning and business outcomes in today’s smart, always-on and data-hungry world. Our innovative, end-to-end solutions portfolio delivers unparalleled scale, performance, and agility, including core to edge IP solutions, cloud-native offers, leading-edge software security and analytics tools, as well as 5G-ready packet and optical networking solutions acquired via our recent merger with ECI Telecom. To learn more about Ribbon visit rbbn.com.

Important Information Regarding Forward-Looking Statements  
The information in this release contains forward-looking statements regarding future events that involve risks and uncertainties. All statements other than statements of historical facts contained in this release, including those regarding future growth, are forward-looking statements. The actual results of Ribbon Communications may differ materially from those contemplated by the forward-looking statements. For further information regarding risks and uncertainties associated with Ribbon Communications’ business, please refer to the “Risk Factors” section of Ribbon Communications’ most recent annual or quarterly report filed with the SEC. Any forward-looking statements represent Ribbon Communications’ views only as of the date on which such statement is made and should not be relied upon as representing Ribbon Communications’ views as of any subsequent date. While Ribbon Communications may elect to update forward-looking statements at some point, Ribbon Communications specifically disclaims any obligation to do so.

Investor Relations

Monica Gould

+1 (212) 871-3927
[email protected]      

North American Press

Dennis Watson

+1 (214) 695-2224
[email protected] 

APAC, CALA & EMEA Press

Catherine Berthier

+1 (646) 741-1974
[email protected] 

Analyst Relations

Michael Cooper

+1 (708) 212-6922
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/ribbon-appoints-steve-mccaffery-as-executive-vice-president-emea-and-apac-sales-301206105.html

SOURCE Ribbon Communications Inc.

Fully allocated with 80% of commitments from four large U.S. Institutional Investors including Wasatch Global

NEW YORK and TORONTO, Jan. 12, 2021 /CNW/ – TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE:TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced an over subscribed, non-brokered private placement for gross proceeds of approximately C$224 million (“the “Offering”) with 80% of commitments from four large U.S. institutional investors including Wasatch Global. The Offering consists of 18,115,623 common shares in the capital of the Company (the “Common Shares”) issued at the price of C$12.35 per Common Share.

“TerrAscend is strategically building depth and scale in some of the largest and highest growth markets in the U.S. cannabis industry,” said Jason Ackerman, CEO and Executive Chairman of TerrAscend. “This financing further solidifies an already strong balance sheet providing the company with ample cash to both accelerate existing expansion plans and simultaneously pursue M&A transactions in additional limited license states.”  

The Company engaged ATB Capital Markets Inc. to advise on the Offering. Subject to customary closing conditions, including applicable CSE approvals, the Offering is expected to close on or about January 26, 2021.

The securities to be issued pursuant to the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act”), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

About TerrAscend

TerrAscend is a leading North American cannabis operator with vertically integrated operations in Pennsylvania, New Jersey, and California in addition to operating as a licensed producer in Canada. TerrAscend operates an award-winning chain of Apothecarium dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities on both the East and West coasts. TerrAscend’s best-in-class cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use market. The Company owns a number of synergistic businesses and brands, including The Apothecarium, Ilera Healthcare, State Flower, Valhalla Confections, and Arise Bioscience Inc. For more information, visit www.terrascend.com.

About Wasatch Global Investors

Wasatch Global Investors is a 100% employee-owned investment manager founded in 1975 and headquartered in Salt Lake City, Utah. Wasatch had $23.8 billion in assets under management as of July 31, 2020. Wasatch Global Investors is registered with the Securities and Exchange Commission under the Investment Advisers Act of 1940.

Forward Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan” and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future outcomes or performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of the anticipated terms and use of proceeds of the Private Placement. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, the risk factors set out in the Company’s annual information form dated May 31, 2019 as supplemented by management’s discussion and analysis dated April 23, 2020 for the year ended December 31, 2019 and other filings with the Canadian securities regulators available under the Company’s profile on SEDAR at www.sedar.com. Furthermore, the forward-looking information contained in this press release are made as of the date hereof and the Company does not undertake any obligation to update or to revise any of the included forward-looking statements or information, whether as a result of new information, future events or otherwise, except as required by applicable law.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.

SOURCE TerrAscend

ALISO VIEJO, Calif., Jan. 12, 2021 /PRNewswire/ — MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB 17 System, designed with the latest microbraid technology, features a lower profile delivery system compatible with the VIA™ 17 microcatheter and includes additional device configurations.  

The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors. When placed inside the aneurysm sac, the WEB device’s proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment. The WEB System received its first PMA approval in late 2018.

“The excellent clinical results we can achieve with intrasaccular flow disruption technology has changed the way we approach the treatment of wide neck bifurcation aneurysms, and the WEB 17 System expands upon that. Now, we can deliver WEB devices using a low-profile system, similar to those used for standard coil embolization,” noted Adam Arthur, M.D. MPH, Director of Cerebrovascular & Endovascular Neurosurgery at Semmes Murphey Neurologic & Spine Institute, Professor of Neurosurgery at the University of Tennessee, and Principal Investigator of the WEB-IT Pivotal Trial.

“The WEB 17 System has been used to enhance care for thousands of patients globally since its initial launch in 2016. MicroVention is proud to bring this expanded portfolio to physicians in the United States, providing more treatment options for patients with complex aneurysms,” said Carsten Schroeder, President and Chief Executive Officer of MicroVention.  

For more information regarding the WEB Aneurysm Embolization System, please visit https://www.microvention.com/product/web-family.

About Wide Neck Bifurcation Aneurysms

An intracranial aneurysm is a bulging, weak area in the wall of an artery that supplies blood to the brain. A weakness located at a junction between two diverging vessels is called a bifurcation aneurysm.

Important Information About the WEB Aneurysm Embolization System

The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms, which may account for up to 35% of all aneurysms. When placed inside the aneurysm sac, the WEB device’s proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment. The pivotal WEB Intrasaccular Therapy Trial (WEB-IT) demonstrated that the WEB System is effective in attaining positive long-term clinical results in a safe, single-device procedure for wide neck bifurcation aneurysms. The WEB Aneurysm Embolization System has been CE marked since 2010 and has been used in more than 12,000 cases and multiple clinical studies throughout the world.

The WEB Aneurysm Embolization system is indicated for use at the middle cerebral artery (MCA) bifurcation, internal carotid artery (ICA) terminus, anterior communicating artery (AComm) complex, or basilar artery apex for the endovascular treatment of adult patients with saccular, wide neck, bifurcation intracranial aneurysms with dome diameter from 3 mm to 10 mm and either neck size 4 mm or greater or the dome-to-neck ratio is greater than 1 and less than 2.

About MicroVention, Inc.
Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases.  In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention into their family of Companies.  Terumo’s acquisition of MicroVention allowed both Companies to leverage their unique, proprietary technologies toward an increased focus on treating cerebrovascular diseases.  Headquartered in California, MicroVention products are sold in more than 75 nations through a direct sales organization alongside strategic distribution partnerships.
www.microvention.com         

About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years.  Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions.  The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since.  Now its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice, such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
www.terumo.com

Media Contact:

Cathy Demyanovich

Sr. Director, Corporate Communications
MicroVention, Inc.
+1-714-247-8000 

View original content:http://www.prnewswire.com/news-releases/lower-profile-web-intrasaccular-aneurysm-treatment-device-receives-fda-approval-301206050.html

SOURCE MicroVention-Terumo, Inc.

LISHUI, China, Jan. 12, 2021 /PRNewswire/ — Farmmi, Inc. (“Farmmi” or the “Company”) (NASDAQ: FAMI), an agriculture products supplier in China, today announced that on January 11, 2021, it received notification from The Nasdaq Stock Market LLC (“NASDAQ”) confirming the Company has regained compliance with NASDAQ’s minimum bid price requirement under Listing Rule 5550(a)(2).  NASDAQ noted this matter is now closed.

About Farmmi, Inc.

Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products.  For further information about the Company, please visit: http://ir.farmmi.com.cn/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including the potential impact of COVID-19 on our business within and outside of China.  These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

 

View original content:http://www.prnewswire.com/news-releases/farmmi-regains-compliance-with-nasdaq-minimum-bid-price-requirement-301205804.html

SOURCE Farmmi, Inc.

• Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
• Hesperidin may help against Covid-19 viral replication
• Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm

MONTREAL, Jan. 12, 2021 /PRNewswire/ – Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical company, provided comments today on a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C”. The complete newsletter is available at: Read+more+about+the+need+for+novel+approaches+to+SARS-CoV-2_v2.pdf[93].pdf (valeo-hesperco.s3.ca-central-1.amazonaws.com)

According to the newsletter, Hesperidin has recently attracted the attention of researchers, because it binds to key proteins of SARS-CoV-2¹. This may interfere with viral entry into host cells⁴.

In Wu et. al (2020),  the screening of 1066 natural substances with potential antiviral effect, plus 78 antiviral drugs already known in the literature for their binding to SARS-CoV-2 proteins, Hesperidin was the only compound  that could target the binding interface between viral Spike proteins and ACE-2 human receptors².

Hesperidin can also bind to 3CLpro – the main protease responsible for the cleavage of SARS-CoV-2 peptides into functional units for virus replication and packaging within the host cells^1,3 . By doing so, it may help against COVID-19 viral replication⁴.  

The newsletter continued that cytokine storm is a major cause of acute respiratory distress syndrome, which is the main reason for hospitalization of COVID-19 patients^5,6.  Chronic inflammation may also contribute to impaired quality of life in COVID-19 survivors⁷. Hesperidin is a potent antioxidant and its anti-inflammatory activity may help in controlling cytokine storm^1,4.

In discussing vitamin C, the newsletter noted that vitamin C did not demonstrate affinity to receptors that would interfere with SARS-CoV-2 infectivity². Further, many studies on the efficacy of vitamin C in preventing respiratory diseases are inconclusive or negative¹. A complementary therapeutic effect of intravenous high doses of vitamin C has been reported and clinical trials are ongoing¹.

In conclusion, the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease¹.

“There is a growing body of scientific evidence suggesting that the flavonoid “Hesperidin” has certain properties that may prove useful in the management of COVID-19″, said Steve Saviuk, Valeo’s President and Chief Executive officer. “Hesperidin can be found in lower dose formats in a number of natural health products. Hesperco^TM, Valeo’s unique Hesperidin formulation, is the only format available where every capsule contains 500mg of concentrated Hesperidin. In addition to being available for online ordering on www.hesperco.com and www.amazon.ca, we anticipate that Hesperco^TM will be available at major retailers across Canada in early 2021″.

Additional scientific information regarding Hesperidin is available at www.ingenewpharma.com, scientific partner to Valeo Pharma Inc.

References:

1. Bellavite P, Donzelli A. Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits. Antioxidants (Basel). 2020;9(8). doi:10.3390/antiox9080742

2. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020;10(5):766-788. doi:10.1016/j.apsb.2020.02.008

3. Liu C, Zhou Q, Li Y, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci. 2020;6(3):315-331. doi:10.1021/acscentsci.0c00272

4. Haggag YA, El-Ashmawy NE, Okasha KM. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? Med Hypotheses. 2020;144:109957. doi:10.1016/j.mehy.2020.109957

5. Chowdhury MA, Hossain N, Kashem MA, Shahid MdA, Alam A. Immune response in COVID-19: A review. J Infect Public Health. 2020;13(11):1619-1629. doi:10.1016/j.jiph.2020.07.001

6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566- 3

7. Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. medRxiv. Published online October 18, 2020:2020.10.15.20205054. doi:10.1101/2020.10.15.20205054

About Hesperco^TM

Hesperco^TM capsules are Valeo’s unique hesperidin formulation and are available in bottles of 60 capsules. Hesperidin is a flavonoid with powerful antioxidant properties that help support the immune system. Hesperco™ is available at www.hesperco.com and www.amazon.ca

About Valeo Pharma

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter. 

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or uinknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

View original content to download multimedia:http://www.prnewswire.com/news-releases/valeo-pharma-highlights-mdbriefcase-newsletter-comparing-hesperidin-and-vitamin-c-for-covid-19-301206174.html

SOURCE Valeo Pharma Inc.

Innovative
‘
Inform
‘
 is first Intelligent Digital Assistant that marries deep data with

ROI-focused marketing initiatives to help wealth managers better communicate  

TORONTO, Jan. 12, 2021 /PRNewswire/ – NexJ Systems Inc. (TSX: NXJ), announces it is partnering with AdvisorStream to enhance a product that enables wealth managers to better address the need to meaningfully engage with clients. Inform is the first intelligent digital assistant that allows advisors to hyper-personalize content and deliver superior, value-added, customer experiences throughout the client lifecycle. 

Awaad Amir, Wealth Management analyst for Celent, the leading research and advisory firm focused on technology for financial institutions globally, advocates the critical need for digital content marketing. Understanding how the NexJ and AdvisorStream partnership benefits the industry Mr. Amir says, “Licensed content usually garners higher levels of engagement over content that’s publicly available. Further, using personalization tools to distribute exclusive content is a powerful and smart client engagement strategy.”

NexJ’s innovative Inform product, coupled with AdvisorStream’s trusted 5-star rated content marketing platform drives higher client acquisition, engagement and retention. All content is exclusively licensed from industry recognized sources, with no paywall or advertisements, and is fully compliant with FINRA, SEC, IIROC and FCA regulations.

How it works:
NexJ’s Inform product leverages information a firm has about a client such as demographic and transaction data to build a unique client interest profile. The profile is further enhanced using the most advanced AI, including Natural Language Processing to analyze client or prospect interests sourced from interactions (like email and notes from the firm’s CRM system).  Once the client or prospect interests have been identified, Inform allows advisors to automatically or manually deliver a stream of content, hyper-personalized to each recipient.

“Our partnership with AdvisorStream is a natural fit. We share a vision of helping wealth managers better engage their clients and facilitate their ability to generate more assets,” says Paul DeVriendt, Senior Vice President of Product at NexJ Systems Inc. “Inform, powered by AdvisorStream, helps wealth managers improve the client experience by delivering relevant and meaningful content with no paywalls or ads, and saves valuable time by automating the selection of content that matches client interests. This builds loyalty by enabling regular, proactive interactions with clients.”

Kevin Mulhern, AdvisorStream CEO and Co-founder says: “Inform answers the call of our enterprise clients for a next-level product that helps maximize the return on the significant investments they have made in CRM technologies. It marries deep data with ROI-focused marketing initiatives. AdvisorStream’s partnership with NexJ is aligned with the goals of wealth managers to cost-effectively manage the unspoken expectations of clients and prospects; to have a deeper understanding of their wants, needs, dreams, concerns and life events and deliver the most relevant, real-time, trusted content through unprecedented hyper-personalization.”

To learn more, please visit the Informwebsite.

About NexJ Systems Inc.
NexJ Systems develops Intelligent Customer Management products for the financial services industry. Its award-winning products are designed to help Wealth Management, Private Banking, Corporate and Commercial Banking, and Insurance firms revolutionize their business. Powered by artificial intelligence, its products help drive productivity, boost client engagement, and increase revenue. With users in over 60 countries, its customers benefit from its deep expertise across financial services verticals, strategic investment in innovation, and commitment to their success.

Based in Toronto, NexJ has clients throughout North America, Asia Pacific and in Europe. For more information about NexJ visit www.nexj.com, e-mail [email protected], or call 416-222-5611. Join us on LinkedIn, follow us on Twitter, subscribe to our YouTube channel, or like us on Facebook.

About AdvisorStream
AdvisorStream is the highest-rated marketing platform for enterprises and financial advisors and is fully partnered with the world’s most credible and trusted publishers. The award-winning platform helps financial firms and advisors engage investors through timely, personalized and compliant communications. As an omni-channel marketing service, AdvisorStream delivers the highest-quality and up-to-date article, commentary, video and infographic content through newsletters, social media, emails, websites, and client portals. Every year, AdvisorStream delivers hundreds of millions of communications materials on behalf of its vast network of financial advisors. Headed by CEO, co-founder and industry thought leader Kevin Mulhern, AdvisorStream has offices in New York, London, and Toronto.

For more information, visit AdvisorStream.com or connect with us on social media on Facebook,  LinkedIn, Twitter, or Instagram.

NexJ Forward-looking Statement
Certain statements in this press release may contain words considered forward-looking statements or information under applicable securities laws. These statements are based on NexJ’s current expectations, estimates, forecasts and projections about the operating environment, economies, and markets in which the company operates. These statements are subject to important assumptions, risks and uncertainties that are difficult to predict, and the actual outcome may be materially different. NexJ’s assumptions, although considered reasonable by the company at the date of this press release, may prove to be inaccurate and consequently, its actual results could differ materially from the expectations set out herein. For additional information with respect to risks and other factors which could occur, see NexJ’s securities filings with the OSC and other securities regulators. NexJ securities filings are available on www.sedar.com.  Unless otherwise required by applicable securities laws, NexJ disclaims any intention or obligations to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:http://www.prnewswire.com/news-releases/nexj-systems-partners-with-advisorstream-to-solve-critical-problem-in-wealth-management-301206108.html

SOURCE NexJ Systems Inc.